10月21日,比利时生物技术公司Galapagos宣布关闭细胞治疗业务,波及欧洲、美国和中国四个国家共计365个岗位。此举源于出售失败,将资金转向“变革性”交易,凸显细胞疗法领域投资冷却。该公司股价应声下跌16%。Galapagos,这家以炎症和纤维化药物闻名的比利时生物科技先锋,正以“壮士断腕”姿态告别细胞治疗。该公司成立于1999年,总部位于比利时梅赫伦,早年因与吉利德合作开发JAK1抑制剂...
Source Link10月21日,比利时生物技术公司Galapagos宣布关闭细胞治疗业务,波及欧洲、美国和中国四个国家共计365个岗位。此举源于出售失败,将资金转向“变革性”交易,凸显细胞疗法领域投资冷却。该公司股价应声下跌16%。Galapagos,这家以炎症和纤维化药物闻名的比利时生物科技先锋,正以“壮士断腕”姿态告别细胞治疗。该公司成立于1999年,总部位于比利时梅赫伦,早年因与吉利德合作开发JAK1抑制剂...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.